A Phase 2 Master Protocol to Assess the Efficacy and Safety of FORE8394, an Inhibitor of BRAF Class 1 and Class 2 Alterations, in Participants with Cancer Harboring BRAF Alterations
| ClinicalTrials.gov Identifier |
| NCT05503797 |
| Principal Investigator |
| N/A |
| Principal Investigator Phone |
| N/A |
| Principal Investigator Email |
| N/A |
| Study Coordinator |
| See full list below |
| Study Coordinator Phone |
| See full list below |
| Study Coordinator Email |
| See full list below |
| Additional Study Coordinators |
|
For additional locations please see https://clinicaltrials.gov/study/NCT05503797 California - Los Angeles University of California Los Angeles Rheumatology - Westwood Johnathan Flores [email protected] California - San Francisco UCSF Helen Diller Family Comprehensive Cancer Center Robert Castillo [email protected] Florida - Miami University of Miami Hospital and Clinics Maria Diaz Alonso [email protected] Maryland - Baltimore The Johns Hopkins Hospital Erin Dailey [email protected] Maryland - Columbia Maryland Oncology Hematology - Columbia Shakyra Tyus [email protected] Massachusetts - Boston Tufts Medical Center Jill Marshall [email protected] Minnesota - Duluth St. Luke's Hospital - Duluth Charity Gonzalez [email protected] Missouri - Saint Louis Chirosree Bandyopadhyay [email protected] Missouri - St. Joseph Mosaic Life Care at Saint Joseph - Medical Center Monica Morrill [email protected] Nebraska - Grand Island Nebraska Cancer Specialists - Midwest Cancer Center - Legacy Brenda Broekemeier [email protected] New Jersey - Morristown Overlook Medical Center Christopher Buck [email protected] New York - New York Columbia University Irving Medical Center Karishma Sookraj [email protected] New York - New York Memorial Sloan Kettering Cancer Center - New York Susan Korte [email protected] Ohio - Toledo Taylor Cancer Research Center Jessica Obarski [email protected] Pennsylvania - Philadelphia Thomas Jefferson University - Center City Rachel Kane [email protected] Rhode Island - Providence Lifespan Cancer Institute - Rhode Island Hospital William Siwik [email protected] Texas - Dallas Baylor Scott & White Research Institute Chinwe Onyekonwu [email protected] Texas - Temple, TX Baylor Scott & White Medical Center - Temple Kharren Woods [email protected] Washington - Seattle University of Washington School of Medicine Hannah Lee [email protected] West Virginia - Morgantown, WV West Virginia University Health Sciences Campus Nina Moore [email protected] |
| Study Overview |
| The purpose of this study is to assess the efficacy and safety of plixorafenib in participants with cancer, including cholangiocarcinoma, who have alterations in a gene called BRAF. |
| Enrollment Information |
| Approximately 250 |
| Study Start Date |
| 20230221 |
| Study End Date |
| 20260828 |
| Financial Assistance Available |
| Yes |